Recombinant Human Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), partial

Code CSB-YP866213HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP866213HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP866213HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP866213HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP866213HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
MALT1
Uniprot No.
Alternative Names
Caspase like protein; DKFZp434L132; IMD12; MALT 1; MALT associated translocation; MALT lymphoma associated translocation; MALT lymphoma-associated translocation; Malt1; MALT1 paracaspase; MALT1_HUMAN; MLT 1; MLT; MLT1; Mucosa associated lymphoid tissue lymphoma translocation gene 1; Mucosa associated lymphoid tissue lymphoma translocation protein 1; Mucosa-associated lymphoid tissue lymphoma translocation protein 1; Paracaspase; Paracaspase-1; PCASP1
Species
Homo sapiens (Human)
Protein Length
Partial
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Protease that enhances BCL10-induced activation: acts via formation of CBM complexes that channel adaptive and innate immune signaling downstream of CARD domain-containing proteins (CARD9, CARD11 and CARD14) to activate NF-kappa-B and MAP kinase p38 pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Mediates BCL10 cleavage: MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Involved in the induction of T helper 17 cells (Th17) differentiation. Cleaves RC3H1 and ZC3H12A in response to T-cell receptor (TCR) stimulation which releases their cooperatively repressed targets to promote Th17 cell differentiation. Also mediates cleavage of N4BP1 in T-cells following TCR-mediated activation, leading to N4BP1 inactivation. May also have ubiquitin ligase activity: binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity.
Gene References into Functions
  1. Cellular metabolism constrains innate immune responses in preterm infants due to perturbations in the expression of PPARgamma, MALT1, DDIT4, and most of the cytokines. PMID: 30446641
  2. this first report show that MALT1 integrates several T-cell activation pathways and indirectly controls gamma-chain receptor dependent survival, to impact on T-cell expansion PMID: 29359407
  3. These findings suggested that cleavage at R781 of MALT1 played a role in the survival of activated B-cell like diffuse large B-cell lymphoma cells. PMID: 29953499
  4. MALT1 and TRAF6 cooperatively interact with CARMA1-BCL10 filaments and form CARMA1-BCL10-MALT1-TRAF6 signalosome. PMID: 29382759
  5. The results suggest that the involvement of MALT1 in DNA damage-induced NF-kappaB is through the recruitment of TRAF6. PMID: 28717989
  6. A missense mutation in mucosa-associated lymphoid tissue lymphoma translocation 1 gene (MALT1) was identified in a family with siblings with IPEX-Like Syndrome. MALT1 deficiency should now be considered as a possible cause of IPEX-like syndrome associated with immunodeficiency. PMID: 27253662
  7. Thrombin-mediated MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. PMID: 27681433
  8. Authors utilized transcriptomic data and experimental evidences to prove that miR-181d was a novel regulator of NFkappaB signaling pathway by directly repressing MALT1, leading to induced PN markers and reduced MES genes. PMID: 28286260
  9. Taken together, this present study indicates that miR-649 promotes herpes simplex virus type 1 replication through regulation of the MALT1-mediated antiviral signaling pathway and suggests a promising target for antiviral therapies. PMID: 27813118
  10. These results demonstrate a key role for the proteolytic activity of MALT1 in PEL, and provide a rationale for the pharmacological targeting of MALT1 in PEL therapy. PMID: 27538487
  11. MALT1 deficiency or pharmacological inhibition of MALT1 catalytic activity inhibits pathogenic mutant CARD14-induced cytokine and chemokine expression in human primary keratinocytes. PMID: 27113748
  12. CARD14/MALT1-mediated signaling in keratinocytes has a role in psoriasis [review] PMID: 27939769
  13. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation PMID: 27071417
  14. Studies indicate that t(11;18)(q21;q21) translocation involves MALT1 (MALT lymphoma translocation protein 1) gene. PMID: 26386283
  15. Targeting MALT1 proteolytic activity in autoimmune disease and B-cell lymphoma might not be a successful strategy. (Review) PMID: 26787500
  16. Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). PMID: 26540570
  17. TCR-induced alternative splicing augments MALT1 scaffolding to enhance downstream signalling and to promote optimal T-cell activation. PMID: 27068814
  18. MALT1 protease activity has a central role in keratinocyte immunity PMID: 26767426
  19. Data show that caspase recruitment domain-containing protein 11/B-cell CLL/lymphoma 10/mucosa-associated lymphoid tissue lymphoma translocation gene 1 signaling drives lymphoproliferation through NF-kappa B and c-Jun N-terminal kinase activation. PMID: 26668357
  20. MALT1-dependent NF-kappaB activation is crucial for the development of EGFR-associated solid-tumor progression PMID: 25982276
  21. Backbone Assignment of the MALT1 Paracaspase by Solution NMR. PMID: 26788853
  22. The MALT1-mediated HOIL-1 cleavage provides a gain-of-function mechanism that is involved in the negative feedback regulation of NF-kappaB signaling. PMID: 26573773
  23. The MALT1 is a key player in the activation of the NF-kappa B upon antigen receptor stimulation and lymphocyte activation. PMID: 26716947
  24. Comparative analysis of the active site suggests that paracaspases constitute one of the several subclasses of metacaspases that have evolved several times independently. PMID: 26377317
  25. An overview of the present understanding of MALT1's function is presented. [review] PMID: 26507244
  26. By regulating linear ubiquitination, MALT1 is both a positive and negative pleiotropic regulator of the human canonical NF-kappaB pathway. PMID: 26525107
  27. MALT1 uses multiple strategies to ensure NF-kappaB activation and target gene expression. (Review) PMID: 25996250
  28. data demonstrate that MALT1 ubiquitination is critical for the engagement of CBM and IKK complexes, thereby directing platelet signals to the NF-kappaB pathway. PMID: 25748427
  29. API2-MALT1 induces paracaspase-mediated cleavage of the tumour suppressor protein LIMA1. PMID: 25569716
  30. The strongest hypermethylation signal in type 2 diabetes mellitus is in the promoter of the MALT1 gene, involved in insulin and glycemic pathways, and related to taurocholate levels in blood. PMID: 25502755
  31. Absence of the carcinoma cell-specific mutation suggests that the inactivation of MALT1 expression but not the mutation promotes oral carcinoma progression PMID: 22752732
  32. This is q review of the understanding of MALT1 function and regulation, and the development of small molecule MALT1 inhibitors for therapeutic applications. PMID: 25285878
  33. MALT1 auto-proteolysis is essential for NF-kappaB-dependent gene transcription in activated lymphocytes. PMID: 25105596
  34. Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of A20, which enhances NF-kappaB signaling and may be related to T-ALL pathogenesis. PMID: 25384343
  35. MALT1 exerts its effect upon immune response through the initiation of cellular miR-2909 RNomics. PMID: 25500259
  36. The MALT1 and MALT1-V1 variant expression level was downregulated in rheumatoid arthritis patients. PMID: 24971370
  37. In the crystal structure of human MALT1casp-Ig3 in complex with the tricyclic phenothiazine derivative thioridazine the inhibitor is bound in a hydrophobic pocket far from the active site. PMID: 23946259
  38. This review highlights the recent advances in the normal and disease-related functions of MALT1 PMID: 24004675
  39. Combined immunodeficiency associated with homozygous MALT1 mutations. PMID: 24332264
  40. our study implicates RIP1 ubiquitination as a critical component of API2-MALT1-dependent lymphomagenesis PMID: 23770847
  41. Taken together, loss of MALT1 expression alters keratin expression and enhances proliferation of carcinoma cells, and may progress oral carcinomas into the advanced state. PMID: 23799590
  42. Glutamate 549 at the dimerization interface is required for the formation of the enzymatically active, monoubiquitinated form of MALT1. PMID: 23977204
  43. Structure-guided mutagenesis confirmed the observed interfaces in Bcl10 filament assembly and MALT1 activation in vitro and NF-kappaB activation in cells. PMID: 24074955
  44. Overexpression of MALT1 partially rescues HECTD3 depletion-induced apoptosis. PMID: 23358872
  45. USP2a plays an important role in TCR signaling by deSUMOylating TRAF6 and mediating TRAF6-MALT1 interaction PMID: 23264041
  46. observations demonstrate MALT1 represses genes activating the aggressive phenotype of carcinoma cells, and MALT1 acts as a tumour suppressor and the loss of expression stimulates oral carcinoma progression PMID: 23778523
  47. Report t(14;18)(q32;q21) involving IGH-MALT1 in extranodal diffuse large B-cell lymphomas of the breast and testis. PMID: 23018871
  48. monoubiquitination of MALT1 is essential for its catalytic activation and is therefore a potential target for the treatment of ABC-DLBCL and for immunomodulation. PMID: 23416615
  49. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. PMID: 23238016
  50. These phenothiazines selectively inhibit cleavage activity of recombinant and cellular MALT1 by a noncompetitive mechanism. PMID: 23238017

Show More

Hide All

Involvement in disease
Immunodeficiency 12 (IMD12)
Subcellular Location
Cytoplasm, perinuclear region. Nucleus.
Protein Families
Peptidase C14B family
Tissue Specificity
Highly expressed in peripheral blood mononuclear cells. Detected at lower levels in bone marrow, thymus and lymph node, and at very low levels in colon and lung.
Database Links

HGNC: 6819

OMIM: 604860

KEGG: hsa:10892

STRING: 9606.ENSP00000319279

UniGene: Hs.601217

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1